Angiotensin receptor blockers: Focus on cardiac and renal injury

详细信息    查看全文

• 作者：Somasundaram Arumugam ; MPharm ; PhD^a ; Remya Sreedhar ; MPharm ; PhD^a ; Rajarajan A. Thandavarayan ; MPharm ; PhD^a ; ^b ; Vengadeshprabhu Karuppagounder ; MPharm ; PhD^a ; Prasanna Krishnamurthy ; MVSc ; PhD^b ; Kenji Suzuki ; MD ; PhD^c ; Masahiko Nakamura ; MD ; PhD^d ; Kenichi Watanabe ; MD ; PhD^a ; ^{watanabe@nupals.ac.jp" class="auth_mail" title="E-mail the corresponding author} ; ^{somasundaram143@gmail.com" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Renin angiotensin system ; Angiotensin receptor blocker ; Heart failure ; Diabetes mellitus ; Hypertension
• 刊名：Trends in Cardiovascular Medicine
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：26
• 期：3
• 页码：221-228
• 全文大小：1135 K

文摘

Angiotensin II, an important component of renin angiotensin system, is a potent vasopressor and its actions are mostly mediated via angiotensin II type 1 receptor (AT₁R) and role of AT₂R in counterbalancing the actions of AT₁R stimulation are under extensive research. In addition to its physiological actions, angiotensin II plays important roles in the pathogenesis of atherosclerosis, hypertension, left ventricular hypertrophy, and heart failure. The effects of angiotensin II can be blocked by either suppressing its production by blocking angiotensin converting enzyme or by antagonizing its actions on AT₁R using angiotensin II receptor blockers (ARBs). Instead of the extensive use of ARBs in the treatment of various cardiovascular diseases, proper selection of a particular ARB is crucial as the clinical condition of individual patient is different and also their economic status would play an essential role in medication compliance. Thus a critical review of the proven and promising actions of ARBs against various pathological conditions will be of great importance for the clinicians as well as for the researchers.